血浆总cfDNA是转移性黑色素瘤肿瘤负荷的替代标志物及生存预后标志物
这项前瞻性生物标志物队列研究在43例转移性黑色素瘤患者中评估血浆总游离DNA(cfDNA)作为肿瘤负荷和预后标志物的潜力。基线cfDNA浓度与治疗前肿瘤负荷相关(ρ=0.52,P<0.001),且cfDNA≥89 pg/μl与更短的总生存期显著相关(10.0 vs 22.7个月,P=0.009)。cfDNA变化与肿瘤负荷的治疗相关变化相关(ρ=0.49,P=0.002)。
要点
- 基线cfDNA与转移性黑色素瘤肿瘤负荷相关(ρ=0.52,P<0.001)。
- cfDNA≥89 pg/μl者总生存期更短(10.0 vs 22.7个月,P=0.009)。
- cfDNA变化与肿瘤负荷的治疗相关变化相关(ρ=0.49,P=0.002)。
核心结论
- cfDNA是转移性黑色素瘤患者肿瘤负荷的替代标志物,并对总生存期具有预后价值。
研究设计与样本
- 前瞻性生物标志物队列研究,纳入43例转移性黑色素瘤患者,其中38例有治疗前和首次疗效评估时的配对血液采集和影像评估。
主要发现
- 基线cfDNA浓度与治疗前肿瘤负荷相关(ρ=0.52,P<0.001)。
- 基线cfDNA水平与死亡风险和总生存期显著相关,cut off值89 pg/μl识别出两个不同预后组(高cfDNA的HR=2.22,P=0.004)。
- cfDNA≥89 pg/μl患者总生存期更短(10.0 vs 22.7个月,P=0.009;高cfDNA的HR=2.22,P=0.004),多变量分析中与乳酸脱氢酶(LDH)比较时显著性维持。
- cfDNA变化与肿瘤负荷的治疗相关变化相关(ρ=0.49,P=0.002)。
- 基线cfDNA与肿瘤负荷的比值具有预后价值(cfDNA/肿瘤体积≥8 pg/(μl*cm3)的HR=2.7,P=0.024)。
关键数值与推荐
- cfDNA cut off值89 pg/μl用于区分预后组(高cfDNA的HR=2.22,P=0.004)。
- cfDNA/肿瘤体积比值≥8 pg/(μl*cm3)与预后相关(HR=2.7,P=0.024)。
临床怎么用
- cfDNA可作为转移性黑色素瘤肿瘤负荷的替代标志物,辅助预后评估。
- 基线cfDNA水平及治疗中变化可用于监测肿瘤负荷变化和生存预后。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Tumour burden is a prognostic biomarker in metastatic melanoma. However, tumour burden is difficult to measure and there are currently no reliable surrogate biomarkers to easily and reliably determine it. The aim of this study was to assess the potential of plasma total cell free DNA as biomarker of tumour burden and prognosis in metastatic melanoma patients. MATERIALS AND METHODS: A prospective biomarker cohort study for total plasma circulating cell-free DNA (cfDNA) concentration was performed in 43 metastatic melanoma patients. For 38 patients, paired blood collections and scan assessments were available before treatment and at first response evaluation. Tumour burden was calculated as the sum of volumes from three-dimensional radiological measurements of all metastatic lesions in individual patients. RESULTS: Baseline cfDNA concentration correlated with pre-treatment tumour burden (ρ = 0.52, P < 0.001). Baseline cfDNA levels correlated significantly with hazard of death and overall survival, and a cut off value of 89 pg/μl identified two distinct prognostic groups (HR = 2.22 for high cfDNA, P = 0.004). Patients with cfDNA ≥89 pg/μl had shorter OS (10.0 versus 22.7 months, P = 0.009; HR = 2.22 for high cfDNA, P = 0.004) and the significance was maintained when compared with lactic dehydrogenase (LDH) in a multivariate analysis. We also found a correlation between the changes of cfDNA and treatment-related changes in tumour burden (ρ = 0.49, P = 0.002). In addition, the ratio between baseline cfDNA and tumour burden was prognostic (HR = 2.7 for cfDNA/tumour volume ≥8 pg/(μl*cm3), P = 0.024). CONCLUSIONS: We have demonstrated that cfDNA is a surrogate marker of tumour burden in metastatic melanoma patients, and that it is prognostic for overall survival.
引用
- Valpione S, Gremel G, Mundra P, et al. Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients. Eur J Cancer. 2017. PMID: 29175734. doi:10.1016/j.ejca.2017.10.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。